3:35 PM
 | 
Jul 03, 2014
 |  BC Extra  |  Company News

FDA approves Spectrum's belinostat

FDA granted accelerated approval to Beleodaq belinostat from Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). The approval came nearly a month ahead of the Aug. 9 PDUFA date....

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >